News

Company News: Curetis – Study Data Presented at ECCMID 2019 Confirm Clinical Benefits of Unyvero Platform

— Growing body of evidence shows benefits of Unyvero for antibiotic stewardship

— 8 new reports on European studies presented by clinical researchers using Unyvero HPN, ITI, BCU and IAI

Curetis N.V. (the “Company” and, together with Curetis USA Inc. and Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that novel products, data, and services will be presented during this year’s European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam, The Netherlands, from April 13 – 16, 2019. Curetis can be found at booth 1.65 during the conference.

As part of the scientific program of the conference, several of Curetis´ Unyvero Application Cartridges for the detection of pathogens and antimicrobial resistance (AMR) markers in severe infections are featured in a total of eight scientific contributions summarizing clinical studies conducted by independent clinical research groups.

As an example, in a clinical study of the Unyvero HPN Application Cartridge for pneumonia Unyvero would have led to changes in antibiotic therapy in 37 of 56 evaluated clinical episodes, i.e. in two thirds of patients (Poster #1559). In another study of the Unyvero BCU Application Cartridge in patients with hospital-acquired bloodstream infections, the researchers concluded that the use of Unyvero BCU would have allowed an early adaptation of antimicrobial therapy in 48.5% of cases of gram-negative blood stream infections (Poster #2362).

These studies add to a growing body of clinical evidence across many countries in Europe, the U.S. and Asia on the value proposition that Unyvero offers to clinicians around the world in assessing and – if needed – adapting the antibiotic therapy regimen based on rapid molecular diagnostic test results.

During ECCMID 2019, the Company will also showcase its Unyvero A30 RQ Platform, which is in advanced stages of development and available for partnering. Moreover, the Company will introduce its Unyvero AMR Atlas, a knowledge base on AMR markers featured on Unyvero Application Cartridges for pneumonia (HPN / LRT) as well as novel, next-generation sequencing services for public health and the pharmaceutical industry, both developed by Curetis’ subsidiary Ares Genetics.

Contributions to the scientific program of ECCMID 2019 related to Unyvero Applications:

Unyvero HPN – Hospitalized Pneumonia:

Poster
#1553:
Comparison study of the Curetis Unyvero platform with routine microbiological culture of broncho-alveolar lavage specimens for detection of pathogens and associated resistance mechanisms, and the potential impact on management of pneumonia in the ICU setting
Lucinda Barrett, McKechnie Stuart, Jones Emma-LouisePS090 Molecular diagnostics of respiratory tract pathogens
Monday, April 15, 2019 – 12:30 – 13:30
Poster #1559: Impact of the Unyvero HPN test in intensive care unit patients with ventilator-associated pneumonia or severe hospital-acquired pneumonia
Peiffer-Smadja N, Bouadma L, Allouche K, Reboul M, Montravers P, Timsit J-F, Armand-LefèvrePS090 Molecular diagnostics of respiratory tract pathogens
Monday, April 15, 2019 – 12:30 – 13:30
Poster
#1563:
Appropriateness of antimicrobial prescribing for hospital-acquired and ventilator-associated pneumonia (HAP/VAP) in UK ICUs assessed against PCR-based molecular diagnostic tests
Virve Enne, Rossella Baldan, Charlotte Russell, Alp Aydin, Hollian Richardson, Dewi Owen, Brenda Nomamiukor, Juliet High, Antony Colles, David Brealey, Federico Ricciardi, Julie Barber, Ann Marie Swart, Justin O’Grady, Vanya Gant and David M Livermore on behalf of the INHALE WP2 Study GroupPS090 Molecular diagnostics of respiratory tract pathogens
Monday, April 15, 2019 – 12:30 – 13:30
Poster
#1561:
An observational study comparing the performance of two multiplex PCR platforms against routine microbiology for the detection of potential pathogens in patients with suspected hospital-acquired/ventilator-associated pneumonia (HAP/VAP) across 15 UK intensive care units (ICUs)
Virve I. Enne, Alp Aydin, Hollian Richardson, Dewi Owen, Rossella Baldan, Charlotte Russell, Brenda Nomamiukor, Ann Marie Swart, Juliet High, Antony Colles, Federico Ricciardi, Julie Barber, Vanya Gant, David M. Livermore and Justin O’Grady on behalf of the INHALE WP1 Study GroupPS090 Molecular diagnostics of respiratory tract pathogens
Monday, April 15, 2019 – 12:30 – 13:30

Unyvero BCU – Blood Culture

Poster
#2362:
Clinical evaluation of the Blood Culture UNYVERO (BCU) assay for the diagnosis of hospital-acquired bloodstream infection – preliminary results
G. Péan de Ponfilly, H. Benmansour, AL Munier, E. Lecorche, F. Mougari, H. Jacquier, E. CambauPS134 – Advances in bloodstream infection diagnostics
Tuesday, April 16, 2019 – 12:30-13:30

Unyvero ITI – Implant & Tissue Infections

Poster
#2512:
How reliable is the new generation of multiplex PCR in the diagnosis of periprosthetic joint infection?
Lausmann C, Citak M, Abdelaziz H, Gehrke T, Zahar A.PS090 Molecular diagnostics of respiratory tract pathogens
Monday, April 15, 2019 – 12:30 – 13:30
Poster
#1577
Diagnostic performances and therapeutic impact of the Unyvero ITI multiplex PCR in periprosthetic joint infections

Boisset S., Richarme C., Pavese P., Duval B. R., Pierre I, Seurat O.

PS090 Molecular diagnostics of respiratory tract pathogens
Monday, April 15, 2019 – 12:30 – 13:30

Unvero IAI – Intra-Abdominal Infections

Poster
#1587:
Performance of the automated multiplex-PCR Unyvero IAI application in the management of complicated intra-abdominal infections
Simon Klifa, Catherine Dunyach-Remy, Claire Roger, Hélène Marchandin, Jean- Yves Lefrant, Laurent Muller, Albert Sotto, Jean-Philippe LavignePS090 Molecular diagnostics of respiratory tract pathogens
Monday, April 15, 2019 – 12:30 – 13:30